{
    "name": "pegademase",
    "comment": "Discontinued",
    "other_names": [
        "Adagen"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/adagen-pegademase-342862",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Not known if distributed into breast milk, use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not known if distributed into breast milk, use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Use as a preparatory/support therapy for bone marrow transplantation",
                "Severe thrombocytopenia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in patients with thrombocytopenia; contraindicated in patients with severe thrombocytopenia",
                "Monitor plasma ADA activity & red blood cell dATP levels",
                "Development of antibodies reported, which may result in rapid clearance; adjust dose as necessary in patients developing antibodies",
                "Risk for infection increases in patients that are not able to maintain adequate levels of plasma ADA",
                "Not a substitute for bone marrow transplant"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "pentostatin",
            "description": {
                "common": "pentostatin decreases effects of pegademase by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pentostatin is a potent inhibitor of adenosine deaminase (pegademase)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegloticase",
            "description": {
                "common": "pegloticase will decrease the level or effect of pegademase by  Other (see comment). Use Caution/Monitor. According to the manufacturer, potential for anti-PEG antibody development that may bind to other pegylated drugs; clinical significance unknown"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegvaliase",
            "description": {
                "common": "pegvaliase, pegademase. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hematologic events",
            "percent": null
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        },
        {
            "name": "autoimmune hemolytic anemia",
            "percent": null
        },
        {
            "name": "thrombocythemia",
            "percent": null
        },
        {
            "name": "thrombocytopenia and autoimmune thrombocytopenia",
            "percent": null
        },
        {
            "name": "Dermatological events",
            "percent": null
        },
        {
            "name": "Injection site erythema",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Lymphomas",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        }
    ]
}